Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus
Plasmodium. If not treated appropriately, human P. falciparum malaria can quickly become …

Introduction Artemisinin-based combination therapies (ACTs) are recommended first-line
antimalarials for uncomplicated Plasmodium falciparum malaria. Pharmacokinetic …

The pharmacogenetics of antimalarial agents are poorly known, although the application of
pharmacogenetics might be critical in optimizing treatment. This population pharmacokinetic …

Highlights•New targets and resistance determinants have been identified for ACT partner
drugs.•Resistance to many of the ACT partner drugs involves multifactorial mechanisms.• …

Artemisinin is an antimalarial compound derived from the plant Artemisia annua L., also
known as sweet wormwood. According to the World Health Organization, artemisinin‐based …

Introduction: Plasmodium falciparum malaria is one of the world's most lethal infectious
diseases, commanding millions of drug administrations per year. The pharmacogenetics of …

The first-line treatments for uncomplicated Plasmodium falciparum malaria are artemisinin-
based combination therapies (ACTs), consisting of an artemisinin derivative combined with …

Introduction: Artemisinin-based combination therapy (ACT) is used extensively as first-line
treatment for uncomplicated falciparum malaria. There has been no rigorous assessment of …

Considering malaria is a highly devastating disease of mankind, total eradication of malaria
seems to be an uphill task, the only relief from this disease is achieved by usage of …

Background Inter-individual variability in plasma concentration-time profiles might contribute
to differences in anti-malarial treatment response. This study investigated the …